NEW YORK (Genomeweb News) – Vermillion reported after the close of the market Thursday that its second quarter revenues were essentially flat year over year at $324,000 versus $323,000 in Q2 2013.

The company posted product revenue of $211,000, flat with $210,000 in Q2 2013. That revenue was based on 4,223 OVA1 ovarian cancer tests performed in Q2 2014 versus 4,184 tests performed in the year-ago period.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.